M. Rhee

发表

A Randomized Study of Tenofovir Disoproxil Fumarate in Treatment-experienced HIV-1 Infected Adolescents

K. White, S. Chuck, J. Pinto, 2012, The Pediatric infectious disease journal.

A Randomized, Open-Label Study of the Safety and Efficacy of Switching Stavudine or Zidovudine to Tenofovir Disoproxil Fumarate in HIV-1–infected Children With Virologic Suppression

K. White, J. Church, S. Chuck, 2015, The Pediatric infectious disease journal.

A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results.

K. White, J. Rockstroh, N. Clumeck, 2014, Journal of acquired immune deficiency syndromes.

Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF in HIV-Infected Patients With Mild-to-Moderate Renal Impairment

F. Post, A. Cheng, C. Beraud, 2015, Journal of acquired immune deficiency syndromes.

Cobicistat-Boosted Protease Inhibitors in HIV-Infected Patients with Mild to Moderate Renal Impairment

F. Post, M. Ramgopal, M. Fisher, 2014, HIV clinical trials.

Risk factors for proteinuria in HIV-infected and -uninfected Hispanic drug users.

C. Schmid, L. Stevens, M. Rhee, 2008, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Tenofovir alafenamide plus emtricitabine versus abacavir plus lamivudine for treatment of virologically suppressed HIV-1-infected adults: a randomised, double-blind, active-controlled, non-inferiority phase 3 trial.

D. Podzamczer, A. Winston, M. Das, 2018, The lancet. HIV.

Safety, efficacy, and pharmacokinetics of single-tablet elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in virologically suppressed, HIV-infected children: a single-arm, open-label trial.

Yongwu Shao, D. Porter, A. Gaur, 2017, The Lancet. Child & adolescent health.

Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial.

D. Ward, J. Gallant, M. Johnson, 2016, The lancet. HIV.

Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results.

F. Antunes, J. Gallant, J. Fehr, 2013, The Journal of infectious diseases.

The renal-bone axis in older people living with HIV on stable antiretroviral therapy: A sub-analysis of the GS-US-104-0423 study

W. Tinago, F. Jouret, L. Campbell, 2022, Antiviral therapy.

Relationship Between Plasma Protease Inhibitor Concentrations and Lipid Elevations in HIV Patients on a Double‐Boosted Protease Inhibitor Regimen (Saquinavir/Lopinavir/Ritonavir)

D. Greenblatt, C. Cohen, M. Rhee, 2010, Journal of clinical pharmacology.

A Randomized Double-Blind Comparison of Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate for Initial Treatment of HIV-1 Infection: Analysis of Week 96 Results

K. White, P. Sax, A. Zolopa, 2013, Journal of acquired immune deficiency syndromes.

Brief Report: Long-Term (96-Week) Efficacy and Safety After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected, Virologically Suppressed Adults

J. Gallant, E. Daar, A. Clarke, 2017, Journal of acquired immune deficiency syndromes.

Absence of Lenacapavir (GS-6207) Phenotypic Resistance in HIV Gag Cleavage Site Mutants and in Isolates with Resistance to Existing Drug Classes

M. Rhee, Renee R Ram, N. Margot, 2020, Antimicrobial Agents and Chemotherapy.

The association of HIV viral load with indirect markers of liver injury

N. Terrin, B. McGovern, M. Rhee, 2012, Journal of viral hepatitis.

Bioequivalence of Two Co-formulations of Emtricitabine/TenofovirAlafenamide Fixed-Dose Combinations with 200/10 mg and 200/25 mg

B. Kearney, J. Koziara, M. Rhee, 2016 .

Elvitegravir/cobicistat/emtricitabine/tenofovir DF (Quad) has durable efficacy and differentiated safety compared to efavirenz/emtricitabine/tenofovir DF at week 96 in treatment‐naïve HIV‐1‐infected patients

A. Zolopa, J. Gallant, C. Cohen, 2012 .

A Randomized, Double-Blind Comparison of Single-Tablet Regimen Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Versus Single-Tablet Regimen Efavirenz/Emtricitabine/Tenofovir DF for Initial Treatment of HIV-1 Infection: Analysis of Week 144 Results

K. White, P. Sax, A. Zolopa, 2014, Journal of acquired immune deficiency syndromes.

Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection.

J. Baeten, H. Stellbrink, H. Dvory‐Sobol, 2022, The New England journal of medicine.

Lenacapavir: a first-in-class HIV-1 capsid inhibitor.

H. Dvory‐Sobol, N. Shaik, M. Rhee, 2022, Current opinion in HIV and AIDS.

Clinical targeting of HIV capsid protein with a long-acting small molecule

J. R. Somoza, W. Sundquist, Xiaohong Liu, 2020, Nature.

Resistance analyses in Highly Treatment-Experienced People with HIV Treated with the Novel Capsid HIV Inhibitor Lenacapavir.

H. Dvory‐Sobol, M. Rhee, N. Margot, 2022, The Journal of infectious diseases.

HIV Drug Therapy in the Americas Congress, 13 – 15 June 2013, São Paulo, Brazil

M. Lederman, D. Kuritzkes, K. White, 2013, Journal of the International AIDS Society.

1585. Efficacy and safety of long-acting subcutaneous lenacapavir in heavily treatment-experienced people with multi-drug resistant HIV: Week 52 results

J. Baeten, H. Dvory‐Sobol, J. Molina, 2022, Open Forum Infectious Diseases.

73. Interim Resistance Analysis of Long-Acting Lenacapavir in Treatment-Naïve People with HIV at 28 Weeks

H. Dvory‐Sobol, Ross Martin, M. Rhee, 2021, Open Forum Infectious Diseases.

Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial.

Yongwu Shao, D. Porter, D. SenGupta, 2016, The lancet. HIV.

International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK

Raúl Tabarés Gutiérrez, Samit R. Joshi, H. Jessen, 2016, Journal of the International AIDS Society.

Switching from ritonavir to cobicistat in HIV patients with renal impairment who are virologically suppressed on a protease inhibitor

M. Ramgopal, G. Moyle, M. Fisher, 2014, Journal of the International AIDS Society.

Pharmacologic Consideration for the Use of Antiretroviral Agents in the Elderly

D. Greenblatt, M. Rhee, 2008, Journal of clinical pharmacology.

International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK

Samit R. Joshi, Charlene A Flash, Thomas Lengauer, 2014 .

Investigation of the Interactions between Methadone and Elvitegravir-Cobicistat in Subjects Receiving Chronic Methadone Maintenance

R. D. Bruce, G. Friedland, B. Kearney, 2013, Antimicrobial Agents and Chemotherapy.

The Pharmacokinetic and Pharmacodynamic Interactions Between Buprenorphine/Naloxone and Elvitegravir/Cobicistat in Subjects Receiving Chronic Buprenorphine/Naloxone Treatment

R. D. Bruce, G. Friedland, B. Kearney, 2013, Journal of acquired immune deficiency syndromes.

Efficacy and safety of emtricitabine/tenofovir alafenamide (FTC/TAF) vs. emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) as a backbone for treatment of HIV-1 infection in virologically suppressed adults: subgroup analysis by third agent of a randomized, double-blind, active-controlled phase 3

A. Lazzarin, Y. Yazdanpanah, F. Post, 2017, HIV clinical trials.

A Randomized Phase 3 Study Comparing Once-Daily Elvitegravir With Twice-Daily Raltegravir in Treatment-Experienced Subjects With HIV-1 infection: 96-Week Results

D. Cooper, B. Conway, S. Chuck, 2013, Journal of acquired immune deficiency syndromes.

Virological Outcomes of EVG/COBI/FTC/TDF and EVG/COBI/FTC/TAF in Antiretroviral-Naive HIV-1-Infected Participants with Baseline HIV-1 RNA ≥1,000,000 Copies/ml: A Post Hoc Analysis of Phase III Clinical Trials

K. White, P. Sax, M. Das, 2018, Antiviral therapy.

Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial.

J. Baeten, Samir K. Gupta, M. Ramgopal, 2023, The lancet. HIV.

Elvitegravir/cobicistat/emtricitabine/tenofovir DF (Quad) has durable efficacy and differentiated safety compared to atazanavir boosted by ritonavir plus emtricitabine/tenofovir DF at week 96 in treatment‐naïve HIV‐1‐infected patients

J. Gathe, E. Dejesus, M. Fordyce, 2012 .

Pharmacokinetics and Safety of Boosted Elvitegravir in Subjects with Hepatic Impairment

B. Kearney, S. Ramanathan, M. Rhee, 2014, Antimicrobial Agents and Chemotherapy.

Phenotypic resistance to lenacapavir and monotherapy efficacy in a proof-of-concept clinical study.

Ross Martin, M. Rhee, N. Margot, 2022, The Journal of antimicrobial chemotherapy.

Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results.

F. Antunes, J. Gallant, J. Fehr, 2013, The Journal of infectious diseases.

Antiviral Activity, Safety, and Pharmacokinetics/Pharmacodynamics of Tenofovir Alafenamide as 10-Day Monotherapy in HIV-1–Positive Adults

U. Bredeek, P. Ruane, D. Berger, 2013, Journal of acquired immune deficiency syndromes.

Week 144 Resistance Analysis of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF versus Efavirenz/Emtricitabine/Tenofovir DF in Antiretroviral-Naive Patients

K. White, A. Cheng, M. Rhee, 2015, Antiviral therapy.